NCT04696731View on ClinicalTrials.gov

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Interventions
GENETIC

ALLO-316

ALLO-316 is an allogeneic CAR T cell therapy targeting CD70

BIOLOGICAL

ALLO-647

ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

DRUG

Fludarabine

Chemotherapy for lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for lymphodepletion

Trial Locations (10)

10065

Memorial Sloan Kettering Cancer Center, New York

20007

Georgetown University Hospital, Washington D.C.

33612

Moffitt Cancer Center, Tampa

48201

Karmanos Cancer Institute, Detroit

77030

MD Anderson Cancer Center, Houston

90095

UCLA Medical Center, Los Angeles

91010

City of Hope, Duarte

94143

UCSF Medical Center, San Francisco

97213

Providence Portland Medical Center, Portland

06520

Yale School of Medicine, New Haven

Sponsors
All Listed Sponsors
lead

Allogene Therapeutics

INDUSTRY

NCT04696731 - Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter